Hematologic Diseases  >>  Tracleer (bosentan)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tracleer (bosentan) / J&J, Roche
NCT00310830: Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
3
14
US, Europe
Bosentan
Actelion
Pulmonary Hypertension
08/07
08/07
ASSET-3, NCT00360087 / 2006-000374-75: A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET Study

Terminated
3
236
US, Europe
Bosentan
Actelion, National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Hypertension, Sickle Cell Anemia
08/07
12/07
ASSET-2, NCT00313196: Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH)

Terminated
3
12
US, Europe
bosentan
Actelion
Pulmonary Hypertension
08/07
08/07

Download Options